660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)
oleh: Linghua Wang, Jianjun Gao, Wei Qiao, Arlene Siefker-Radtke, Matthew Campbell, Amishi Shah, Rahul Sheth, Omar Alhalabi, Sangeeta Goswami, Charles Guo, Sergio P Klimkowsky, Tharekeswara Bathala, Jianfeng Chen, Xinmiao Yan, Ana Adriazola
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2023-11-01 |
Deskripsi
No description available for this item.